This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.

Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers ADCs have become mainstream therapies ...

While chemotherapy is a very commonly used cancer therapy, it frequently causes serious side effects. Antibody-drug conjugates (ADCs) are a promising emerging cancer therapy that combines the ...

Fina Biosolutions announces that the United States Patent and Trademark Office has issued a patent for expression and purification of the conjugate vaccine protein CRM 197 in E. coli. CRM 197 is a key ...